Novo Nordisk's reimbursement appeal goes unheard, Sanofi insulin deemed equivalent
![A trip to the pharmacy for users of Novo Nordisk's Fiasp could become more expense going forward. The Danish Medicines Agency's Reimbursement Committee has recommended a adjusting the fast-acting insulin's reimbursement scheme for the worse.](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13493152.ece/ALTERNATES/schema-16_9/20191003-110216-3-1920x1079we.jpg)
The Danish Medicines Agency has received the Reimbursement Committee's final recommendation for a revision pertaining to the reimbursement scheme for insulin products – and it doesn't bode well for Novo Nordisk.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.